

2009 should be better for investors, valuations are at all time lows but dark clouds still loom.

Sustainability, regulatory achievement, risk factors and capital structure will be the determinants of investor confidence

We all want to live longer, feel better when sick and address the issues of aging. The ability to access better healthcare is also one of the major issues for each of us and the new government administration. The next generation of new drugs, device and diagnostics should come from the emerging company category. Some good news, the FDA approved more drugs and dozens of applications of new formulations or new uses of existing drugs in 2008 than in the previous three years.

But, which emerging public healthcare companies will perform best after the current credit crisis and which will perform worst? It is impossible to predict which of these investments could provide return over the long term to make the risk worth taking. We have experienced the pitfalls of volatility and lack of liquidity; however, the 2009 market will also focus greater emphasis on transparency, governance and risk factors.

As a credible analyst, I now have a greater challenge in framing forward-looking sustainability data as I benchmark an emerging healthcare company's development and regulatory strategy that defines potential appreciation. I do not want to add pages to an already comprehensive review as it is the value of the intelligence/information, not the volume, which is the key! Investors are demanding a higher degree of accountability from the sell-side. At Scimitar, I understand the need for unbiased intelligence.

More important, a consistent flow of coverage attracts and retains a constituency of investment professional who rarely act without multiple research input. I reiterate that press releases don't articulate the resulting impact to invite an investor initiative. An actionable investment thesis and real-time valuation model define the applicability of company newest release or initiatives. We pride ourselves on our differentiated research to assist with investor decision making.

Scimitar Equity provides a wide range of customized research services to align investor sentiment, retain investors and potentially stifle a broker/fund rotation to generate valuation appreciation. Now six years old we improve valuation by indexing the short, near and long term catalysts to facilitate share price discovery and recovery. Our coverage has played a key role stimulating price appreciation and opens doors delivering fund/retail access.

Targeted initiatives in analyst coverage are needed for this unfolding year, 2009; qualify and quantify investor sentiment as it affects stock pricing. An evolving valuation model must benchmark any change/news of milestones or capitalization versus comparable analysis to facilitate portfolio attraction and retention.

If you are interested in becoming a client or have questions regarding any of our services, please contact us about stimulating your valuation through research coverage and access to the asset management, institutional and the retail communities. Review our website: www.scimitarequity.com; E-mail me at: hwm@scimitarequity.com or simply give me a call at 1.508.276.1741 or 617.559.1080 (mobile).

Henry W. McCusker
Founder and Director of Research
Scimitar Equity, LLC